Press Releases Items Per Page 102550 Year None2023202220212020201920182017201620152014 04-20-2023 Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6% 04-19-2023 David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany 04-18-2023 Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy 04-17-2023 Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference 03-30-2023 Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update 03-23-2023 Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023 03-01-2023 Daré Bioscience to Present at the 35th Annual Roth Conference 02-22-2023 Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1 02-01-2023 Daré Bioscience to Participate in Three February Conferences 01-26-2023 Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Next page next › Last page last » Displaying 31 - 40 of 41
04-20-2023 Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%
04-19-2023 David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany
04-18-2023 Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy
04-17-2023 Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference
03-23-2023 Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023
02-22-2023 Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
01-26-2023 Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms
